OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 34
Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 34
Showing 1-25 of 34 citing articles:
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 187
Dario Giugliano, Lorenzo Scappaticcio, Miriam Longo, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 187
Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
Jae‐Seung Yun, Seung‐Hyun Ko
Metabolism (2021) Vol. 123, pp. 154838-154838
Open Access | Times Cited: 181
Jae‐Seung Yun, Seung‐Hyun Ko
Metabolism (2021) Vol. 123, pp. 154838-154838
Open Access | Times Cited: 181
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Bo Xu, Shaoqian Li, Bo-Kyeong Kang, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 116
Bo Xu, Shaoqian Li, Bo-Kyeong Kang, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 116
SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs
Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 86
Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 86
Myricetin ameliorated prediabetes via immunomodulation and gut microbiota interaction
Yang Li, Yongchao Gao, Jupeng Gong, et al.
Food Frontiers (2022) Vol. 3, Iss. 4, pp. 749-772
Open Access | Times Cited: 43
Yang Li, Yongchao Gao, Jupeng Gong, et al.
Food Frontiers (2022) Vol. 3, Iss. 4, pp. 749-772
Open Access | Times Cited: 43
SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies
Annamaria Mascolo, Cristina Scavone, Lucia Scisciola, et al.
Pharmacological Research (2021) Vol. 172, pp. 105836-105836
Open Access | Times Cited: 46
Annamaria Mascolo, Cristina Scavone, Lucia Scisciola, et al.
Pharmacological Research (2021) Vol. 172, pp. 105836-105836
Open Access | Times Cited: 46
Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation
Αndreas S. Papazoglou, Αναστάσιος Κάρτας, Dimitrios V. Moysidis, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 34
Αndreas S. Papazoglou, Αναστάσιος Κάρτας, Dimitrios V. Moysidis, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 34
Dario Giugliano, Miriam Longo, Paola Caruso, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. 7, pp. 1672-1676
Closed Access | Times Cited: 38
The Role of NLRP3 Inflammasome in Diabetic Cardiomyopathy and Its Therapeutic Implications
Kai Ding, Chao Song, Heng-Jing Hu, et al.
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-19
Open Access | Times Cited: 24
Kai Ding, Chao Song, Heng-Jing Hu, et al.
Oxidative Medicine and Cellular Longevity (2022) Vol. 2022, pp. 1-19
Open Access | Times Cited: 24
Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues
Miriam Longo, Lorenzo Scappaticcio, Paolo Cirillo, et al.
Biomolecules (2022) Vol. 12, Iss. 2, pp. 272-272
Open Access | Times Cited: 23
Miriam Longo, Lorenzo Scappaticcio, Paolo Cirillo, et al.
Biomolecules (2022) Vol. 12, Iss. 2, pp. 272-272
Open Access | Times Cited: 23
The residual cardiorenal risk in type 2 diabetes
Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 24
Dario Giugliano, Maria Ida Maiorino, Giuseppe Bellastella, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 24
Two years with GIOIA ‘Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes’: A prospective, multicentre, quasi‐experimental study on sodium‐glucose cotransporter 2 and dipeptidyl peptidase‐4 inhibitors in diabetes clinical practice
Miriam Longo, Paola Caruso, Lorenzo Scappaticcio, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 4, pp. 1492-1501
Closed Access | Times Cited: 3
Miriam Longo, Paola Caruso, Lorenzo Scappaticcio, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 4, pp. 1492-1501
Closed Access | Times Cited: 3
Anti-diabetic agents and the risks of dementia in patients with type 2 diabetes: a systematic review and network meta-analysis of observational studies and randomized controlled trials
Zonglin Li, Chu Lin, Xiaoling Cai, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 3
Zonglin Li, Chu Lin, Xiaoling Cai, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 3
Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
Kazushi Uneda, Yuki Kawai, Takayuki Yamada, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 21
Kazushi Uneda, Yuki Kawai, Takayuki Yamada, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 21
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Therapy for the Primary and Secondary Prevention of Heart Failure in Patients With and Without Type 2 Diabetes Mellitus: A Systematic Review
Maureen Wahinya, Zahid Khan
Cureus (2023)
Open Access | Times Cited: 8
Maureen Wahinya, Zahid Khan
Cureus (2023)
Open Access | Times Cited: 8
Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
Meir Schechter, Cheli Melzer Cohen, Aliza Rozenberg, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 19
Meir Schechter, Cheli Melzer Cohen, Aliza Rozenberg, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 19
Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy
Peter Galis, Linda Bartosova, Veronika Farkašová, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 2
Peter Galis, Linda Bartosova, Veronika Farkašová, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 2
Hypertension in diabetes care: emerging roles of recent hypoglycemic agents
Atsushi Tanaka, Koichi Node
Hypertension Research (2021) Vol. 44, Iss. 8, pp. 897-905
Closed Access | Times Cited: 15
Atsushi Tanaka, Koichi Node
Hypertension Research (2021) Vol. 44, Iss. 8, pp. 897-905
Closed Access | Times Cited: 15
The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
Mariana Cornelia Tilinca, Robert Aurelian Tiucă, Ioan Ţilea, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 12, pp. 1249-1249
Open Access | Times Cited: 13
Mariana Cornelia Tilinca, Robert Aurelian Tiucă, Ioan Ţilea, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 12, pp. 1249-1249
Open Access | Times Cited: 13
Biomarkers of autoimmunity and beta cell metabolism in type 1 diabetes
Meiling Yang, Richard G. Kibbey, Mark J. Mamula
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 9
Meiling Yang, Richard G. Kibbey, Mark J. Mamula
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 9
The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
Klaudia Kowalska, Piotr Wilczopolski, Dominika Buławska, et al.
Antioxidants (2022) Vol. 11, Iss. 12, pp. 2500-2500
Open Access | Times Cited: 8
Klaudia Kowalska, Piotr Wilczopolski, Dominika Buławska, et al.
Antioxidants (2022) Vol. 11, Iss. 12, pp. 2500-2500
Open Access | Times Cited: 8
Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations
Alper Sönmez, Hani Sabbour, Akram Echtay, et al.
Journal of Diabetes (2022) Vol. 14, Iss. 5, pp. 315-333
Open Access | Times Cited: 7
Alper Sönmez, Hani Sabbour, Akram Echtay, et al.
Journal of Diabetes (2022) Vol. 14, Iss. 5, pp. 315-333
Open Access | Times Cited: 7
The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes
Zengguang Kuang, Ningning Hou, Chengxia Kan, et al.
International Urology and Nephrology (2022) Vol. 55, Iss. 3, pp. 617-629
Closed Access | Times Cited: 7
Zengguang Kuang, Ningning Hou, Chengxia Kan, et al.
International Urology and Nephrology (2022) Vol. 55, Iss. 3, pp. 617-629
Closed Access | Times Cited: 7
Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents
Atsushi Tanaka, Shigeru Toyoda, Takumi Imai, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 9
Atsushi Tanaka, Shigeru Toyoda, Takumi Imai, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 9
Sodium–glucose cotransporter-2 inhibitor alleviated atrial remodeling in STZ-induced diabetic rats by targeting TLR4 pathway
Xiaoping Zhan, Lijun Cheng, Ning Huo, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 6
Xiaoping Zhan, Lijun Cheng, Ning Huo, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 6
